Tempest Therapeutics Q3 net loss per share narrows on lower R&D expenses
TPST•Tempest Therapeutics reported a Q3 net loss per share of $0.21, narrower than a year earlier, and ended the quarter with $0.9 million in cash, down from $7.7 million at year-end 2025. The company expects its existing cash to fund operations for less than 12 months.
1. Quarterly results and cash
Tempest Therapeutics reported a Q3 net loss per share of $0.21, narrower than the prior year. Research and development expenses fell following portfolio reprioritization after an asset acquisition, partly offset by costs related to CAR-T candidates. Cash was $0.9 million at quarter-end, compared with $7.7 million at year-end 2025.
2. Pipeline outlook
The company expects to present initial data from its TPST-4903 Phase 1 study at an upcoming conference. It also expects an investigator-initiated trial for TPST-4003 in myasthenia gravis or multiple sclerosis to begin in Q4 2026. Tempest said existing cash is expected to fund operations for less than 12 months.
